Influenza Vaccine Market Set for Stupendous Growth by 2012

As per our new research report "Global Vaccine Market Forecast to 2012", the global influenza market has been growing at a very healthy rate for the past few years despite the high entry barriers to the influenza vaccine market, such as biological manufacturing know-how and complex public and private business interrelationships. Extensive research and profound analysis performed for the market together exhibited a high growth potential market with promising future growth prospects. With increasing researches to develop new alternative technologies for manufacturing pandemic flu vaccines as well as with the support of governments across the globe, the market is projected to grow at a CAGR of around 6% during 2009-2012.

We have done thorough research and prudent analysis of global vaccine market and have identified some critical factors acting as a catalyst for the industry's current and future growth. The report reveals that new vaccination coverage targets set by international health authorities are driving renewed investments in the influenza market. Moreover, the key benefits of influenza vaccines such as having a higher probability of R&D success and long product lifecycles with a negligible threat of generic substitution will pave the way for the growth of the market in coming years by drawing more investments. Based on some concrete market fundamentals, we anticipate that the influenza vaccine market will register one of the most impressive growth rates in the overall vaccine market globally during our forecast period and will become one of the most dominating market segments in the vaccine industry.

The systematic and thorough research gives an insight into the various segments of the global vaccine market, including Therapeutics Vaccines, Influenza Vaccines, Adult/Travel vaccines, Basic Pediatric Vaccines, Proprietary Pediatric Vaccines, and Enhanced Pediatric Vaccines. The comprehensive analysis of the market has identified pediatric vaccines as the highest shareholder at present, but future will see a revival of the market when adult, therapeutic and influenza vaccine segments post a rapid growth.

"Global Vaccine Market Forecast to 2012" also provides valuable information on the key competitors in the market along with their business profile and areas of expertise. The report shows a highly concentrated market structure, with the top four players dominating the market. Moreover, it provides valuable information on recent M&A activity in the sector.

For more information visit: http://www.rncos.com/Report/IM153.htm